Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Barrow Hanley Credit Partners: Lens on Credit Series | Fed Moves Expected Impacts on Leveraged Finance Markets

Fed Moves: Expected Impacts on Leveraged Finance Markets Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Fed Moves: Expected Impacts on Leveraged Finance Markets

Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies.

More about Chet Paipanandiker, Portfolio Manager

More about Nick Losey, Portfolio Manager

Video TranscriptExpand ↓

What is it that we expect for the Fed to do here when it comes to rates? And what is that probably going to do to credit markets and more specifically, leveraged finance markets? So, you know, the Fed was previously expecting to raise rates by about 75 basis points, potentially take rates to probably that 3.75 to 400 basis points in 2023. Expectations now are actually that rates come off a tad from that. In terms of the upper bound by 2023, we're probably thinking more about that 3 and 1/2 range. And really where is the Fed was thinking about more of 100 basis points of increase here at this next Fed meeting, we're actually thinking it's probably going to be closer to 75. A lot of indications on the inflation side or actually starting to turn around, whether it's the job market, early indications of stress there or even in terms of rents. While we are seeing nationwide rents rise, there are some indications that you're going to potentially see more supply, perhaps on the multifamily side, but also in terms of single family housing. Well, the spec builds out there. And so as a result, you know, our expectation is rate increases probably are not going to pace at the level they were given what expectations were in the last couple of months. So what does that mean for leveraged finance markets in terms of how balance sheets are going to handle that? So one of the better markets to look at is actually high yield because of the prevalence of data that you can actually take a look at. And so if you were to assume we kind of top out that 3 and 1/2 rate and take a look at what that does to coverage ratios, what you'll see is buy quality level across high yield. For example, with double B's, you probably see about 12% of free cash flow eaten up by rising rates. If you swing down to single B's, you actually see probably close to 24 to 25% of free cash flow eaten up with triple C's. It's a little bit different. Most of the cash flow of CCC is that free cash flow. Triple C's is actually eaten up by rate hikes, but notice at least 90% of the market or so has good resiliency in terms of rate hikes relative to free cash flow for these companies just by virtue of the double B's and the single B's. If the Fed is more aggressive on the up side and inflation does not subside in some of the numbers that we are seeing and we do see the Fed get pushed rates all the way up to 4% wanted. Do you think there would be one, an inverted yield curve, which would significantly slow the velocity of money? Now, when it comes to the direct impact on high yield, we do think that there would be really got to focus on the fundamentals. Now, high yield has really migrated to a much higher quality index than it had been in the past. In 2007, about 35% of the index was double B's. Now that's about fifth, a little over 50% And so when we step back and look at just the quality of the high yield index, the quality is so much greater than what it has been in the past. So I do think from a fundamental aspect, there's not as much fundamental volatility within the panels and the balance sheets of high yield companies. And as Chad had mentioned earlier, we just went through COVID. When you think about management teams, we're very defensive. From March 2020 upwards to basically summer of 2021, the liquidity levels on balance sheets are still at historically high levels. So there is a lot of defensive ability within these balance sheets on top of a lower volatility from just a high level perspective. And then also looking backwards for a couple of decades to prove the point on a higher quality high yield index, you know, you've seen margins drift higher over time. And CapEx requirements drift lower while leverage levels has basically stayed at roughly the same level. So when it comes to cash flow conversion and the ability to service debts, high yields, it's an extremely good spot. And then as Fed raises rates over time, high yield issuers do have fairly low floating rate exposure overall. And so their direct impact to the channel is less than the leveraged loan issuers themselves. So that ability to service that debt is just extended longer until they actually end up having to refi, refi their debt. And I'm touching on kind of that refi wall is like the last kind of four or five years. High yield companies have really used this low rate environment to push out maturities. So we don't have a lot of near-term maturities that companies have to deal with. Now Higher rates and higher economic volatility, pressure on margins that will impact on the margin, the high yield companies. But that's where active management comes into play and where basically solid fundamental analysis, picking good companies, you'll have good returns with significantly less risk. When you look at the defaults environment, you know, it tends to really be driven by the CCC exposure in. And the index where, we just philosophic kind of run a little bit lower triple C's and take that CCC exposure when it makes sense to do so.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Adonis’ new CPO and first CRO signals AI RCM vendors are shifting from pilots to platform operating models

Adonis’ new CPO and first CRO signals AI RCM vendors are shifting from pilots to platform operating models

Adonis has appointed a new Chief Product Officer (CPO) and promoted its first Chief Revenue Officer (CRO), following a successful $40 million Series C funding round and a fourfold increase in revenue. This move underscores a shift among AI RCM vendors, like Adonis, from pilot projects to platform-based operating models. This transition is expected to result in more structured product roadmaps and a strong emphasis on value demonstration for health systems.

  • 01Adonis appointed a new CPO and promoted its first CRO.
  • 02The company achieved a $40 million Series C funding and a fourfold revenue increase.
  • 03AI RCM vendors are moving from pilot projects to platform operating models.

Aug 22, 2026

Maureen Sanders - Vice Chair, Healthconnect Texas

Maureen Sanders serves as the Vice Chair at HealthConnect Texas, a prominent organization in the healthcare sector. The organization focuses on improving patient care and healthcare delivery.

  • 01HealthConnect Texas is dedicated to improving healthcare delivery.
  • 02Maureen Sanders holds the position of Vice Chair at HealthConnect Texas.

Aug 21, 2026

Bobby Hilliard - Board Chair, HealthConnect Texas

Bobby Hilliard is the Board Chair of HealthConnect Texas, an organization operating in the healthcare sector. HealthConnect Texas focuses on improving healthcare connectivity and accessibility. The organization aims to streamline healthcare services and enhance patient outcomes.

  • 01HealthConnect Texas is focused on enhancing healthcare connectivity and accessibility.
  • 02The organization aims to improve healthcare service efficiency and patient outcomes.
  • 03Bobby Hilliard serves as the Board Chair of HealthConnect Texas.

Aug 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512